Trial reportPloS one2018
Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Ligilactobacillus salivarius alleviated intestinal damage induced by Salmonella in mice via regulating microbiota.BMC microbiology · 2025Article
- Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease.Journal of fungi (Basel, Switzerland) · 2025Review
- Gut mycobiome alterations and implications for liver diseases.PLoS pathogens · 2024Review
- Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites.Scientific reports · 2023Article
- Fungal infections and the fungal microbiome in hepatobiliary disorders.Journal of hepatology · 2023Review
- Roles for the mycobiome in liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2022Review
- Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities.Microbiome · 2021Review
- Development and Analysis of qPCR for the Identification of Arthroconidial Yeasts of the Genus Magnusiomyces.Mycopathologia · 2021Article
- Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.Frontiers in medicine · 2021Review
- From Birth and Throughout Life: Fungal Microbiota in Nutrition and Metabolic Health.Annual review of nutrition · 2020Article
- Shotgun-Metagenomics on Positive Blood Culture Bottles Inoculated With Prosthetic Joint Tissue: A Proof of Concept Study.Frontiers in microbiology · 2020Article
- Gut Mycobiota in Immunity and Inflammatory Disease.Immunity · 2019Review
- Short-Term Probiotic Administration Increases Fecal-AntiMicroorganisms · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with liver cirrhosis are susceptible to fungal infections. Due to low sensitivity of culture-based methods, we applied a real-time PCR assay targeting the 18S rRNA gene in combination with direct sequencing and terminal-restriction fragment length polymorphism (T-RFLP) in order to establish a novel tool to detect fungal DNA and to quantify and differentiate Candida DNA, also in polyfungal specimens. In total, 281 samples (blood n = 135, ascites n = 92, duodenal fluid n = 54) from 135 patients with liver cirrhosis and 52 samples (blood n = 26, duodenal fluid n = 26) from 26 control patients were collected prospectively. Candida DNA was quantified in all samples. Standard microbiological culture was performed for comparison. Blood and ascites samples, irrespective of the patient cohort, showed a method-independent low fungal detection rate of approximately 1%, and the Candida DNA content level did not exceed 3.0x10(1) copies ml-1 in any sample. In contrast, in duodenal fluid of patients with liver cirrhosis high fungal detection rates were discovered by using both PCR- and culture-based techniques (81.5% vs. 66.7%; p = 0.123) and the median level of Candida DNA was 3.8x10(5) copies ml-1 (2.3x10(2)-6.3x10(9)). In cirrhosis and controls, fungal positive culture results were confirmed by PCR in 96% and an additional amount of 44% of culture negative duodenal samples were PCR positive. Using T-RFLP analysis in duodenal samples, overall 85% of results from microbial culture were confirmed and in 75% of culture-negative but PCR-positive samples additional Candida species could be identified. In conclusion, PCR-based methods and subsequent differentiation of Candida DNA might offer a quick approach to identifying Candida species without prior cultivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.